Health Boards
›
Psoriasis In The News
AbbVie and Boehringer Ingelheim to develop and commercialize BI 655066
|
AbbVie and Boehringer Ingelheim to develop and commercialize BI 655066
|
Tue-27-09-2016, 18:50 PM
(Tue-27-09-2016, 17:44 PM)mataribot Wrote: There probably several reasons that are over my head. Interesting thoughts, but like you it's all over my head too. 
|
|
« Next Oldest | Next Newest »
|
| Possibly Related Threads… | |||||
| Thread | Author | Replies | Views | Last Post | |
|
Obese children more likely to develop psoriasis | Fred | 2 | 740 |
Thu-22-08-2024, 19:53 PM Last Post: Fred |
|
|
AbbVie will present data on risankizumab at EADV | Fred | 3 | 5,610 |
Mon-26-09-2016, 17:07 PM Last Post: jiml |
|
|
Psoriasis clear 66 months after one subcutaneous injection of trial drug BI 655066 | Fred | 11 | 16,207 |
Tue-08-03-2016, 19:10 PM Last Post: D Foster |
|
|
New psoriasis treatment BI 655066 worked faster than Stelara | Fred | 3 | 5,101 |
Thu-08-10-2015, 13:48 PM Last Post: jiml |
|
|
Queen Mary University to develop a targeted approach to psoriasis treatment | Fred | 18 | 26,241 |
Sat-30-11-2013, 12:05 PM Last Post: jiml |
However, my guess is the maintenance dose is not enough. The further away you get from the loading dose or if you miss a dose the more problems you have.